AI 401

Drug Profile

AI 401

Alternative Names: AI-401; Recombinant human insulin - AutoImmune

Latest Information Update: 09 Jun 2010

Price : $50

At a glance

  • Originator AutoImmune
  • Developer AutoImmune; National Institute of Diabetes and Digestive and Kidney Diseases; University of Turku
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 21 May 2007 Phase-III clinical trials in Type-1 diabetes-mellitus prevention in Canada (PO)
  • 21 May 2007 Phase-III clinical trials in Type-1 diabetes-mellitus prevention in USA (PO)
  • 21 May 2007 Phase-III clinical trials in Type-1 diabetes-mellitus prevention in Finland (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top